Sales & Marketing News | pharmaphorum

News

J&J builds in medtech with $13.1bn Shockwave buy

Johnson & Johnson has reached a deal to acquire Shockwave Medical for around $13.1 billion, expanding its position in medical devices used to treat heart disease.

News

Amylyx wields axe as it pulls ALS drug from the market

Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug

News

President Joe Biden and Senator Bernie Sanders

Biden slams asthma inhaler prices in White House address

President Joe Biden has reiterated his pledge to take action against high drug prices and “beat big pharma,” singling out the cost of asthma inhalers in a speech delivered

News

Basilea Pharmaceutica, ceftobiprole antibiotic

Basilea completes ceftobiprole marathon with FDA approval

Basilea Pharmaceutica will finally be able to bring its antibiotic ceftobiprole to the US market, around 15 years after the drug was first turned down by the FDA.

News

EMA starts review of Rocket’s Fanconi anaemia gene therapy

Patients in the EU with Fanconi anaemia (FA) could soon have the first gene therapy option for the disorder, as the EMA starts a review of Rocket Pharma’s RP-L102 candidat

News

AZ, Daiichi Sankyo file Dato-DXd for second indication

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (

J&J builds in medtech with $13.1bn Shockwave buy

Amylyx wields axe as it pulls ALS drug from the market

Biden slams asthma inhaler prices in White House address

Basilea completes ceftobiprole marathon with FDA approval

EMA starts review of Rocket’s Fanconi anaemia gene therapy

AZ, Daiichi Sankyo file Dato-DXd for second indication

Astellas pays $285m for Audax cancer drug, and other deals

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks